Bortezomib is effective in primary plasma cell leukemia [2]

Leukemia and Lymphoma

Volumn 47, Issue 8, 2006, Pages 1670-1673

  Finnegan, Damian P J ^a   Kettle, Paul ^a   Drake, Mary ^a   Matthews, Christine ^a   Alexander, H Denis ^a   Popat, Rakesh ^b   Cavanagh, Jamie D ^b   Wachsman, William ^c   Morris, T C M ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METHYLPREDNISOLONE; THALIDOMIDE; VALACICLOVIR; VINCRISTINE;

ADULT; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPILEPTIC STATE; FEMALE; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LETTER; MALE; PLASMA CELL LEUKEMIA; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

BONE MARROW EXAMINATION; BORONIC ACIDS; FEMALE; HUMANS; LEUKEMIA, PLASMA CELL; LEUKEMIA, PLASMACYTIC; MALE; MIDDLE AGED; PYRAZINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33748573643     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500520954     Document Type: Letter

References (15)

1. Adams, J and Palombella, V and Sausville, E and Johnson, J and Destree, A and Lazarus, D and (1999) Proteasome inhibitors: A novel class of potent and effective antitumor agents Cancer Res, 59, pp. 2615-2622.
2. Grogan, T and Van Camp, B and Kyle, R and Müller-Hermelink, H and Harris, N.(2001) Plasma cell neoplasms. In WHO Classification of Tumours, Pathology & Genetics - Tumours of Haematopoietic and Lymphoid Tissues. (pp. 142). Lyon: IARC Press.
3. Bladé, J and Kyle, R. (1999) Non-secretory myeloma, immunoglobulin D myeloma, and plasma cell leukaemia Hematol Oncol Clin of North Am, 13, pp. 1259-1272.
4. Drake, M and Morris, C and Hagman, A and Lopponen, T and Bjorkstrand, B and Gahrton, G and (2004) Outcome after autologous transplantation in primary plasma cell leukaemia Bone Marrow Transplant, 33, pp. 112.
5. Bladé, J and Samson, D and Reece, D and Apperley, J and Bjorkstrand, B and Gahrton, G and (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Br J Haematol, 102, pp. 1115-1123.
6. Bradwell, A and Carr-Smith, H and Mead, G and Tang, L and Showell, P and Drayson, M and (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine Clin Chem, 47, pp. 673-680.
7. Richardson, P and Sonneveld, P and Schuster, M and Irwin, D and Stadtmauer, E and Facon, T and (2005) Bortezomib or high-dose Dexamethasone for relapsed multiple myeloma N Engl J Med, 352, pp. 2487-2498.
8. Jagannath, S and Barlogie, B and Berenson, J and Siegel, D and Irwin, D and Richardson, P and (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol, 127, pp. 165-172.
9. Esparis-Ogando, A and Alegre, A and Aguado, B and Mateo, G and Gutierrez, N and Blade, J and (2005) Bortezomib is an efficient agent in plasma cell leukemias Int J Cancer, 114, pp. 665-667.
10. Hideshima, T and Richardson, P and Chauhan, D and Palombella, V and Elliott, P and Adams, J and Anderson, K. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res, 61, pp. 3071-3076.
11. Ma, M and Yang, H and Parker, K and Manyak, S and Friedman, J and Altamirano, C and (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents J Clin Cancer Res, 9, pp. 1136-1144.
12. Mitsiades, N and Mitsiades, C and Richardson, P and Poulaki, V and Tai, Y and Chauhan, D and (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications Blood, 101, pp. 2377-2380.
13. Oakervee, H and Popat, R and Curry, N and Smith, P and Morris, C and Drake, M and (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma Br J Haematol, 129, pp. 755-762.
14. Perez-Simon, J and Garcia-Sanz, R and Tabernero, M and Almeida, J and Gonzalez, M and Fernandez-Calvo, J and (1998) Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes Blood, 91, pp. 3366-3371.
15. Greipp, P and San Miguel, J and Durie, B and Crowley, J and Barlogie, B and Blade, J and (2005) International staging system for multiple myeloma J Clin Oncol, 23, pp. 3412-3420.